This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
|Security||DEST / Destination Maternity Corp. (25065D100)|
|Interim CEO||Weinstein Allen|
|Industry||Women's Clothing Stores|
|Institutional Shares||4,862,487 - 32.37%|
|Common Shares Outstanding||15,021,470 shares (as of 2018-05-05)|
|Institutional Value||$ 15,187,000 USD|
Institutional Stock Ownership and Shareholders()
Destination Maternity Corp. (NASDAQ:DEST) has 38 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4,862,487 shares.
Largest shareholders include
Royce & Associates LLC, Renaissance Technologies LLC, Disciplined Growth Investors Inc /mn, Vanguard Group Inc, Dimensional Fund Advisors Lp, Mondrian Investment Partners LTD, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Invesco Ltd., and Moors & Cabot, Inc..
Destination Maternity Corp. (NASDAQ:DEST) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/dest"><img src="https://images.fintel.io/us-dest-so.png" alt="DEST / Destination Maternity Corp. Institutional Ownership"><a>
|Royce & Associates LLC||769,967||769,967||0.00||2,287||1,994||-12.81|
|DISCIPLINED GROWTH INVESTORS INC /MN||618,474||617,347||-0.18||1,837||1,599||-12.96|
|UBS Group AG||652||335||-48.62||2||1||-50.00|
|ATRIA INVESTMENTS LLC||69,027||62,482||-9.48||179||364||103.35|
|LEVIN CAPITAL STRATEGIES, L.P.||17,435||50,820||191.48||52||1,616||3,007.69|
|TFS CAPITAL LLC||18,314||0||-100.00||59||0||-100.00|
|BRIDGEWAY CAPITAL MANAGEMENT INC||116,155||47,000||-59.54||345||122||-64.64|
|GSA CAPITAL PARTNERS LLP||111,592||111,592||0.00||331||289||-12.69|
|RBC Global Asset Management (U.S.)||737,787||71,518||-90.31|
|Cutler Group LP||4,600||0||-100.00||13||0||-100.00|
|Bank of New York Mellon Corp||12,666||15,920||25.69||38||41||7.89|
|VANGUARD GROUP INC||326,600||424,982||30.12||970||1,101||13.51|
|Investors Research Corp||14,025||14,025||0.00||42||36||-14.29|
|Renaissance Technologies LLC||775,100||729,100||-5.93||2,302||1,888||-17.98|
|WHITTIER TRUST CO||0||12,880||0||293|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||Put||10,300||0||-100.00||31||0||-100.00|
|WHITTIER TRUST CO OF NEVADA INC||0||250||0||6|
|BlackRock Institutional Trust Company, N.A.||249,027||246,496||-1.02||1,766||1,274||-27.86|
|OXFORD ASSET MANAGEMENT||26,462||16,887||-36.18||83||44||-46.99|
|RAYMOND JAMES & ASSOCIATES||0||33,600||0||87|
|BANK OF AMERICA CORP /DE/||8,200||8,200||0.00||25||22||-12.00|
|Resources Investment Advisors, Inc.||200||200||0.00||1||1||0.00|
|TWO SIGMA INVESTMENTS LLC||14,753||0||-100.00||44||0||-100.00|
|Alpine Partners VI, LLC||65,000||0||-100.00||193||0||-100.00|
|BlackRock Advisors LLC||2,770||2,770||0.00||20||14||-30.00|
|Moors & Cabot, Inc.||107,790||116,790||8.35||315||302||-4.13|
|BRANDES INVESTMENT PARTNERS, LP||19,000||0||-100.00||56||0||-100.00|
|A.R.T. Advisors, LLC||66,007||18,306||-72.27||196||47||-76.02|
|BlackRock Fund Advisors||30,906||36,726||18.83||219||190||-13.24|
|MILLENNIUM MANAGEMENT LLC||17,511||0||-100.00||52||0||-100.00|
|Mutual Advisors, Llc||67,100||174|
|FAIRFAX FINANCIAL HOLDINGS LTD/ CAN||70,000||70,000||0.00||207||180||-13.04|
|Dynamic Technology Lab Private Ltd||20,332||0||-100.00||60||0||-100.00|
|GEODE CAPITAL MANAGEMENT, LLC||70,049||70,049||0.00||208||181||-12.98|
|GROUP ONE TRADING, L.P.||13,372||3,256||-75.65||40||8||-80.00|
|DIMENSIONAL FUND ADVISORS LP||331,939||367,824||10.81||986||953||-3.35|
|GROUP ONE TRADING, L.P.||Put||5,000||0||-100.00||15||0||-100.00|
|NORTHERN TRUST CORP||34,797||34,397||-1.15||103||89||-13.59|
|ROYAL BANK OF CANADA||23,609||0||-100.00||70||0||-100.00|
|WELLS FARGO & COMPANY/MN||0||0||0||0|
|BlackRock Investment Management, LLC||2,059||1,931||-6.22||15||10||-33.33|
|Virtu Financial LLC||0||11,210||0||29|
|CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM||61,500||61,500||0.00||183||159||-13.11|
|Mondrian Investment Partners LTD||340,046||340,046||0.00||1,010||966||-4.36|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||56,213||0||-100.00||167||0||-100.00|
|WITTENBERG INVESTMENT MANAGEMENT, INC.||22,000||22,000||0.00||65||57||-12.31|
|Tower Research Capital LLC (TRC)||5,774||1,965||-65.97||17||5||-70.59|
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Related News Stories
With the economy in full-speed-ahead recovery mode, tax cuts boosting earnings and regulation rolling back, this is a great time to be a publicly traded company. And there is no sector that is better able to reap this bountiful harvest better than smaller companies. (1-0)
Good day, ladies and gentlemen. And welcome to the Destination Maternity’s First Quarter Fiscal Year 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder [Technical Difficulty] being recorded. (5-0)
BOSTON (Reuters) - Destination Maternity (DEST.O) named veteran retail executive Marla Ryan as its new chief executive on Wednesday, one week after a group of activist investors took control of the board at the maternity and baby clothing retailer. (5-0)
Destination Maternity (DEST) looks like an attractive buying opportunity as management attempts to turn around its operations while its share price trades at a distressed level. DEST was slow to migrate its operations online, but now that management has made its online presence a priority, the move looks to be gaining traction by way of revenue growth. Moreover, its share price is trading at financial crisis levels, signaling many investors have simply given up on the stock, which could lead to a strong move higher should its operations continue to strengthen. (5-0)
Shareholders at Gullane Capital Partners are betting on a comeback for maternity apparel retailer Destination Maternity. (5-1)
as of ET